Biomimetic elasticity compressed assembly controls rapid intracerebral drug release to reverse microglial dysfunction

Area of Science:

• Neuroscience
• Materials Science
• Biomedical Engineering

Background:

• Microglial dysfunction is a key factor in Alzheimer's disease (AD) pathogenesis.
• Developing targeted therapies to regulate microglial activity is crucial for AD treatment.

Purpose of the Study:

• To design a biomimetic assembly for responsive drug delivery to treat Alzheimer's disease.
• To investigate the efficacy of this assembly in clearing amyloid-beta and mitigating oxidative stress.

Main Methods:

• A polymer-based biomimetic assembly was engineered to encapsulate curcumin (Cur) and ceria nanoparticles (CeO2).
• The assembly is designed to release its payload in response to reactive oxygen species (ROS) present in the brain.
• Apolipoprotein decoration was used to enhance intracerebral transport.

Main Results:

• The biomimetic assembly successfully delivered curcumin and ceria nanoparticles upon ROS detection.
• Curcumin treatment modulated microglia from an amyloid-beta-activated state to a phagocytic state.
• Ceria nanoparticles provided antioxidant protection, preventing microglial mitochondrial damage.
• In vivo studies in AD mice demonstrated microglia-mediated amyloid-beta clearance, neuroprotection, and ROS elimination.

Conclusions:

• The developed biomimetic assembly demonstrates effective microglia-mediated clearance of amyloid-beta in Alzheimer's disease models.
• This approach offers significant neuroprotection and reactive oxygen species elimination.
• The study presents a promising new strategy for Alzheimer's disease therapeutics.